Literature DB >> 18728243

Evaluation of the administration time effect on the cumulative cortisol suppression and cumulative lymphocytes suppression for once-daily inhaled corticosteroids: a population modeling/simulation approach.

Kai Wu1, Navin Goyal, Jeffrey G Stark, Günther Hochhaus.   

Abstract

Inhaled glucocorticoids continue to be first-line therapy in asthma. To improve improving patient compliance, newer inhaled glucocorticoids have been developed for once-a-day treatment. This study was interested in identifying the optimal time of dosing using 2 surrogate markers of glucocorticoid action. A previously published study on the pharmacokinetics and pharmacodynamics (cortisol and blood lymphocyte suppression) of the inhaled glucocorticoids budesonide and fluticasone propionate was reanalyzed using a population pharmacokinetic approach. A stochastic numerical simulation using NONMEM assessed the effects of time of dosing on cortisol (side effect parameter) and blood lymphocytes (side effect and effect parameter). The effects on cortisol were more pronounced when the glucocorticoids were given in the morning, whereas the effects on lymphocytes (an effect controlled by endogenous and exogenous glucocorticoids) were maximized when dosing occurred in the late afternoon or evening. Twice-daily dosing of the same dose resulted in smaller differences between maximum and minimal effects. These were of no clinical relevance. Simulations for once-daily dosing support clinical studies that reported a higher antiasthmatic effect and lower cortisol suppression when once-daily dosing occurs in the evening.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18728243     DOI: 10.1177/0091270008320607

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  7 in total

Review 1.  Pharmacometric Models for Characterizing the Pharmacokinetics of Orally Inhaled Drugs.

Authors:  Jens Markus Borghardt; Benjamin Weber; Alexander Staab; Charlotte Kloft
Journal:  AAPS J       Date:  2015-04-07       Impact factor: 4.009

Review 2.  Assessment of the predictive capability of modelling and simulation to determine bioequivalence of inhaled drugs: A systematic review.

Authors:  Juliet Rebello; Bill Brashier; Sharvari Shukla
Journal:  Daru       Date:  2022-01-30       Impact factor: 4.088

3.  Evidence of hypothalamic-pituitary-adrenal axis suppression during moderate-to-high-dose inhaled corticosteroid use.

Authors:  Ozlem Cavkaytar; Dogus Vuralli; Ebru Arik Yilmaz; Betul Buyuktiryaki; Ozge Soyer; Umit M Sahiner; Nurgun Kandemir; Bulent E Sekerel
Journal:  Eur J Pediatr       Date:  2015-08-09       Impact factor: 3.183

4.  Pharmacokinetics of Budesonide Administered with Surfactant in Premature Lambs: Implications for Neonatal Clinical Trials.

Authors:  Jessica K Roberts; Chris Stockmann; Mar Janna Dahl; Kurt H Albertine; Edmund Egan; Zhenjian Lin; Christopher A Reilly; Philip L Ballard; Roberta A Ballard; Robert M Ward
Journal:  Curr Clin Pharmacol       Date:  2016

5.  Towards a Quantitative Mechanistic Understanding of Localized Pulmonary Tissue Retention-A Combined In Vivo/In Silico Approach Based on Four Model Drugs.

Authors:  Anneke Himstedt; Clemens Braun; Sebastian Georg Wicha; Jens Markus Borghardt
Journal:  Pharmaceutics       Date:  2020-04-29       Impact factor: 6.321

6.  PK/PD modeling of 5-hydroxytryptophan (5-HTP) challenge test with cortisol measurement in serum and saliva.

Authors:  Zheng Guan; Gabriel Jacobs; Hans van Pelt; Joop M A Van Gerven; Jacobus Burggraaf; Wei Zhao
Journal:  Pharmacol Res Perspect       Date:  2020-04

7.  Exposure-Response and Clinical Outcome Modeling of Inhaled Budesonide/Formoterol Combination in Asthma Patients.

Authors:  Hyun-Moon Back; Jong Bong Lee; Anhye Kim; Seon-Jong Park; Junyeong Kim; Jung-Woo Chae; Seung Soo Sheen; Leonid Kagan; Hae-Sim Park; Young-Min Ye; Hwi-Yeol Yun
Journal:  Pharmaceutics       Date:  2020-04-09       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.